Envestnet Asset Management Inc. Has $210.24 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Envestnet Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 34.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 926,699 shares of the medical instruments supplier’s stock after buying an additional 235,058 shares during the period. Envestnet Asset Management Inc.’s holdings in Becton, Dickinson and Company were worth $210,240,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BDX. Wesbanco Bank Inc. lifted its position in Becton, Dickinson and Company by 1.9% in the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after acquiring an additional 48 shares in the last quarter. S.A. Mason LLC raised its stake in shares of Becton, Dickinson and Company by 3.7% in the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after purchasing an additional 50 shares during the period. Hillsdale Investment Management Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier’s stock valued at $694,000 after purchasing an additional 50 shares in the last quarter. Americana Partners LLC boosted its position in shares of Becton, Dickinson and Company by 3.5% during the fourth quarter. Americana Partners LLC now owns 1,520 shares of the medical instruments supplier’s stock worth $345,000 after buying an additional 52 shares during the period. Finally, Picton Mahoney Asset Management grew its holdings in shares of Becton, Dickinson and Company by 61.4% during the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier’s stock worth $32,000 after buying an additional 54 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 597 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $236.51, for a total transaction of $141,196.47. Following the completion of the sale, the executive vice president now directly owns 5,544 shares in the company, valued at $1,311,211.44. This trade represents a 9.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now directly owns 5,741 shares in the company, valued at $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 4,984 shares of company stock valued at $1,147,865 over the last ninety days. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have commented on BDX shares. Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. Barclays increased their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 2nd. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Stock Down 6.1 %

Becton, Dickinson and Company stock opened at $208.03 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company’s 50-day moving average is $230.06 and its 200-day moving average is $231.33. The firm has a market capitalization of $59.73 billion, a PE ratio of 34.56, a P/E/G ratio of 1.63 and a beta of 0.35. Becton, Dickinson and Company has a fifty-two week low of $194.46 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has approved a stock buyback plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 outstanding shares. This repurchase authorization allows the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 31st. Investors of record on Monday, March 10th were paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date of this dividend was Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.